AMGXF: AI 评分 59/100 — AI 分析 (4月 2026)

AnGes, Inc. is a Japanese biopharmaceutical company focused on developing gene-based medical products. Their lead product, HGF Plasmid, targets critical limb ischemia, with additional pipeline programs in inflammation, dermatology, and vaccines.

Key Facts: AI Score: 59/100 Sector: Healthcare

公司概况

概要：

AnGes, Inc., a biopharmaceutical firm based in Japan, specializes in gene-based therapies, notably HGF Plasmid for critical limb ischemia, and is expanding its pipeline through strategic alliances and collaborative research in areas like inflammation, dermatology, and vaccine development, operating within the competitive biotechnology sector.

AMGXF是做什么的？

Founded in 1999 and headquartered in Ibaraki, Japan, AnGes, Inc. is a biopharmaceutical company dedicated to the research and development of gene-based medical products. Originally named AnGes MG, Inc., the company rebranded in July 2017 to AnGes, Inc. Its primary focus is on Hepatocyte Growth Factor (HGF) Plasmid, a gene therapy designed to treat critical limb ischemia, a condition characterized by severely restricted blood flow to the legs. Beyond HGF Plasmid, AnGes is actively developing a diverse pipeline of nucleic acid medicines, including NF-kB Decoy Oligonucleotide, aimed at suppressing inflammation in conditions like low back pain. The company is also pursuing treatments for atopic dermatitis and disc degeneration, as well as medical devices to prevent vascular restenosis. Further expanding its research scope, AnGes is developing cervical intraepithelial neoplasia therapeutic vaccines for cervical cancer and DNA vaccines for high blood pressure in collaboration with Osaka University. AnGes strategically partners with other pharmaceutical companies. These alliances include collaborations with BioMarin Pharmaceutical Inc. to market Naglazyme for mucopolysaccharidosis VI in Japan and with Mitsubishi Tanabe Pharma Corporation to market HGF Plasmid for peripheral arterial disease in the United States and Japan. Additional partnerships include SHIONOGI & CO., LTD. for topical drugs containing NF-kB decoy oligonucleotide for skin diseases, Vical, Inc. for Allovectin in cancer treatment, and Brickell Biotech, Inc. for a coronavirus vaccine in the United States and South America.

AMGXF的投资论点是什么？

AnGes, Inc. presents a high-risk, high-reward investment profile typical of early-stage biotechnology companies. The company's value is primarily tied to the successful development and commercialization of its gene-based therapies, particularly HGF Plasmid for critical limb ischemia. While the company has established partnerships with larger pharmaceutical firms, its financial performance is currently characterized by negative profitability, with a profit margin of -586.1%. Upcoming catalysts include clinical trial results for its pipeline products and potential regulatory approvals. The company's beta of 0.80 suggests lower volatility than the overall market. Investors should closely monitor clinical trial progress, regulatory decisions, and partnership developments to assess the company's long-term potential.

AMGXF在哪个行业运营？

AnGes, Inc. operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential. The industry is driven by innovation in gene therapy, vaccine development, and personalized medicine. AnGes faces competition from established pharmaceutical companies and other biotechnology firms, including AAPGV, ADOCY, EKDHF, EPRXF, and FPHAF, all of whom are developing novel therapies. The success of AnGes depends on its ability to secure regulatory approvals, establish strategic partnerships, and effectively commercialize its products in a rapidly evolving market.

Biotechnology

Healthcare

AMGXF有哪些增长机遇？

HGF Plasmid Commercialization: The successful commercialization of HGF Plasmid for critical limb ischemia represents a significant growth opportunity. The market for treating peripheral arterial disease, which includes critical limb ischemia, is substantial and growing, driven by an aging population and increasing prevalence of diabetes. If approved, HGF Plasmid could capture a significant share of this market, generating substantial revenue for AnGes. The timeline for this growth opportunity depends on regulatory approval processes in Japan and the United States.
NF-kB Decoy Oligonucleotide Development: The development of NF-kB Decoy Oligonucleotide for inflammatory diseases, including low back pain and atopic dermatitis, offers another avenue for growth. The market for anti-inflammatory drugs is large and diverse, with significant unmet needs. Successful clinical trials and regulatory approval could position AnGes as a key player in this market. The timeline for this growth opportunity depends on clinical trial outcomes and regulatory decisions.
Vaccine Development Programs: AnGes's vaccine development programs, including the coronavirus vaccine and cervical intraepithelial neoplasia therapeutic vaccines, represent long-term growth opportunities. The global vaccine market is experiencing rapid growth, driven by the COVID-19 pandemic and increasing awareness of preventative healthcare. Successful development and commercialization of these vaccines could generate significant revenue for AnGes. The timeline for this growth opportunity depends on clinical trial results and regulatory approvals.
Strategic Partnerships: AnGes's strategy of forming strategic partnerships with larger pharmaceutical companies provides access to resources, expertise, and distribution channels. These partnerships can accelerate the development and commercialization of its products, reducing risk and increasing the likelihood of success. The continued cultivation of these partnerships is crucial for AnGes's growth. The timeline for this growth opportunity is ongoing.
Expansion into New Markets: AnGes has the opportunity to expand its geographic reach beyond Japan and the United States. Entering new markets, such as Europe and Asia, could significantly increase its revenue potential. This expansion would require significant investment in marketing, sales, and distribution infrastructure. The timeline for this growth opportunity depends on market research, regulatory approvals, and resource allocation.

Market capitalization of $0.14 billion reflects its position as a small-cap biotechnology company.
Negative P/E ratio of -5.88 indicates the company is currently unprofitable.
Gross margin of 36.7% suggests potential for profitability if sales volume increases.
Profit margin of -586.1% highlights significant losses relative to revenue.
Beta of 0.80 indicates lower volatility compared to the overall market.

AMGXF提供哪些产品和服务？

Develop gene-based medical products.
Research and develop gene therapy for critical limb ischemia.
Develop nucleic acid medicines to suppress inflammation.
Create drugs for treating atopic dermatitis and disc degeneration.
Produce medical devices for the prevention of vascular restenosis.
Develop therapeutic vaccines for cervical cancer.
Research and develop DNA vaccines for high blood pressure.
Collaborate with other companies and universities on research and development.

AMGXF如何赚钱？

Research and development of gene-based therapies.
Out-licensing and partnering with larger pharmaceutical companies for commercialization.
Potential for direct sales of approved products in specific markets.
Collaborative research agreements with universities and other institutions.

Patients suffering from critical limb ischemia.
Patients with inflammatory diseases.
Patients with atopic dermatitis and disc degeneration.
Hospitals and clinics.
Pharmaceutical companies through licensing agreements.

Proprietary gene therapy technology.
Strategic partnerships with established pharmaceutical companies.
Pipeline of novel therapeutic candidates.
Intellectual property protection through patents.

什么因素可能推动AMGXF股价上涨？

Upcoming: Clinical trial results for HGF Plasmid for critical limb ischemia.
Upcoming: Regulatory approval decisions for HGF Plasmid in Japan and the United States.
Ongoing: Progress in the development of NF-kB Decoy Oligonucleotide for inflammatory diseases.
Ongoing: Advancement of vaccine development programs, including the coronavirus vaccine.
Ongoing: Potential for new strategic partnerships with pharmaceutical companies.

AMGXF的主要风险是什么？

Potential: Clinical trial failures for pipeline products.
Potential: Regulatory rejection of HGF Plasmid or other therapies.
Potential: Competition from established pharmaceutical companies.
Ongoing: Limited financial resources and dependence on partnerships.
Ongoing: High research and development costs.

AMGXF的核心优势是什么？

Proprietary gene therapy technology.
Strategic partnerships with established pharmaceutical companies.
Diverse pipeline of therapeutic candidates.
Focus on unmet medical needs.

AMGXF的劣势是什么？

Limited financial resources.
Dependence on partnerships for commercialization.
High research and development costs.
Negative profitability.

AMGXF有哪些机遇？

Successful commercialization of HGF Plasmid.
Expansion into new markets.
Development of new gene-based therapies.
Increased demand for vaccines.

AMGXF面临哪些威胁？

Regulatory hurdles.
Competition from established pharmaceutical companies.
Clinical trial failures.
Patent expirations.

AMGXF的竞争对手是谁？

American Acquisition Partners Group V Inc — Focus on acquiring businesses, not direct competitor in gene therapy. — (AAPGV)
ADOCIA — Specializes in formulations of already-approved therapeutic proteins. — (ADOCY)
Eckert & Ziegler Strahlen- und Medizintechnik AG — Focuses on isotope technology for medical and industrial applications. — (EKDHF)
Eupraxia Pharmaceuticals Inc — Develops therapies for unmet medical needs, including prostate cancer. — (EPRXF)
Farmaceuticos y Alimentos SA — Diversified pharmaceutical and food company. — (FPHAF)

Key Metrics

MoonshotScore: 59/100

Company Profile

CEO: Ei Yamada
Headquarters: Ibaraki, JP
Employees: 55
Founded: 2017

AI Insight

AI analysis pending for AMGXF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does AnGes, Inc. do?

AnGes, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of gene-based medical products. Its lead product is HGF Plasmid, a gene therapy designed to treat critical limb ischemia. The company also has a pipeline of other products in development, including nucleic acid medicines for inflammatory diseases, vaccines, and medical devices. AnGes collaborates with other pharmaceutical companies and universities to advance its research and development efforts.

What do analysts say about AMGXF stock?

AI analysis is pending for AMGXF. Generally, biotechnology stocks are viewed as high-risk, high-reward investments due to the lengthy and uncertain drug development process. Key valuation metrics for biotechnology companies include pipeline potential, clinical trial results, and regulatory approval prospects. Investors should carefully consider these factors before investing in AMGXF.

What are the main risks for AMGXF?

The main risks for AnGes, Inc. include clinical trial failures, regulatory rejection of its products, competition from established pharmaceutical companies, limited financial resources, and dependence on partnerships. As an OTC-listed company, AMGXF carries additional risks related to limited disclosure, low liquidity, and potential for manipulation. Investors should carefully assess these risks before investing.